‘We Are Well Positioned To Succeed’: Organon On US Adalimumab Entry
Exclusive Interview With Organon’s US Biosimilars Commercial Lead, Jon Martin
With Organon’s Humira biosimilar Hadlima reaching the US market earlier this month, the company’s biosimilars commercial lead in the market, Jon Martin, spoke to Generics Bulletin about the seminal event, as well as the company’s commercialization-only business model.
